Newsletter

Subscribe and receive updates on this company

Text STOCKS to 72727 for mobile alerts

We are excited to present ProQR Therapeutics N.V. (NASDAQ: PRQR).

Full DD Report for PRQR

You must become a subscriber to view this report.


Recent News from (NASDAQ: PRQR)

ProQR Announces Results for the First Quarter of 2018
Key updates Eight out of twelve patients have been enrolled in a Phase 1/2 clinical trial of QR-110 in adults and children with LCA 10. Interim data are expected in the second half of 2018, with full data expected during 2019. ProQR and Galapagos N.V. entered into a research collabor...
Source: GlobeNewswire
Date: May, 09 2018 07:00
ProQR Announces Conference Presentations for Axiomer® RNA Editing Technology and QR-313 for DEB
LEIDEN, the Netherlands, April 30, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced that the Company will present at t...
Source: GlobeNewswire
Date: April, 30 2018 07:00
ProQR Provides Enrollment Update on QR-110 Clinical Trial and Highlights Ophthalmology Presentations at ARVO
Key Updates Enrollment is on track in the ongoing Phase 1/2 clinical trial of QR-110 with eight out of twelve patients with LCA 10 enrolled. The trial is on track to announce interim six-month data on safety, effects on vision and retinal structure in the second half of the year. Pr...
Source: GlobeNewswire
Date: April, 23 2018 07:00
ProQR Appoints ADAR Expert Dr. Peter A. Beal to Scientific Advisory Board to Focus on Axiomer® RNA A-to-I Editing Technology
Key Updates Dr. Peter A. Beal joins ProQR’s scientific advisory board, bringing with him tremendous experience in the field of RNA-based therapeutics, particularly in the area of RNA editing. As an expert in the field of ADAR and A-to-I editing, Dr. Beal will be instrumental i...
Source: GlobeNewswire
Date: April, 10 2018 07:00
ProQR to Present at Two Upcoming Conferences
LEIDEN, the Netherlands, April 03, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases including Leber's congenital amaurosis 10, dystroph...
Source: GlobeNewswire
Date: April, 03 2018 07:00
Midday Gainers / Losers (3/26/2018)
Gainers: FINL +30% . DRIO +27% . VTNR +22% . USG +19% . BOSC +14% . TOPS +14% . PRQR +12% . ACRX +12% . TVPT +11% . ABIL +10% . More news on: The Finish Line, Inc., DarioHealth Corp., Vertex Energy, Inc., Stocks on the move, , Read more ...
Source: SeekingAlpha
Date: March, 26 2018 12:44
ProQR to Present at Upcoming Investor Conference
LEIDEN, the Netherlands, March 05, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases including cystic fibrosis, Leber's congenital amaur...
Source: GlobeNewswire
Date: March, 05 2018 07:00
ProQR Announces Results for the Fourth Quarter and Full Year 2017 and Provides Business Update
Key updates Runway into the second half of 2019: cash of €48.0 million at year-end expected to fund operations through anticipated clinical data readouts in three different programs. First patient dosed in the Phase 1/2 safety & efficacy trial for QR-110 in children and ad...
Source: GlobeNewswire
Date: February, 28 2018 07:00
ProQR Supports Rare Disease Day 2018 and Honors Henri A. Termeer
LEIDEN, the Netherlands, Feb. 27, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases including cystic fibrosis, Leber's congenital amauro...
Source: GlobeNewswire
Date: February, 27 2018 07:00
Foundation Fighting Blindness will provide up to $7.5 million in funding to develop ProQR's candidate QR-421a for Usher syndrome type 2A
Foundation Fighting Blindness and ProQR enter into a partnership to develop QR-421a for Usher syndrome type 2A, targeting mutations in exon 13 of the causative USH2A gene. Foundation Fighting Blindness will provide milestone-based co-funding of up to $7.5 million to ProQR to advance th...
Source: GlobeNewswire
Date: February, 12 2018 07:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-175.005.055.254.90207,294
2017-10-104.554.554.64994.5549,557
2017-10-094.604.554.654.5536,367
2017-10-064.654.654.704.6059,347
2017-10-054.604.604.80654.5560,055

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-05-226,34018,07335.0800Short
2018-05-217,250173,2634.1844Cover
2018-05-1819,59456,28734.8109Cover
2018-05-1730,18361,52949.0549Short
2018-05-1612,35317,61670.1238Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on PRQR.


About ProQR Therapeutics N.V. (NASDAQ: PRQR)

Logo for ProQR Therapeutics N.V. (NASDAQ: PRQR)

Not available

 

Contact Information

     

     

    Current Share Structure

       


      Recent Filings from (NASDAQ: PRQR)

      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: May, 16 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: May, 10 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: April, 23 2018
      Statement of beneficial ownership of common stock by certain persons
      Filing Type: SC 13GFiling Source: edgar
      Filing Date: April, 12 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: April, 11 2018
      Filing Type: CT ORDERFiling Source: edgar
      Filing Date: April, 09 2018
      Annual and transition report of foreign private issuers under sections 13 or 15(d)
      Filing Type: 20-FFiling Source: edgar
      Filing Date: March, 30 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: February, 28 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: February, 20 2018
      Amendment to the SC 13G filing
      Filing Type: SC 13G/AFiling Source: edgar
      Filing Date: February, 14 2018

       

       


      Daily Technical Chart for (NASDAQ: PRQR)

      Daily Technical Chart for (NASDAQ: PRQR)


      Stay tuned for daily updates and more on (NASDAQ: PRQR)

      It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

      More to come on (NASDAQ: PRQR)

      Do your DD and if you choose, be ready to go!


       

      The Research: All source information contained in this email is from the public sources mentioned below.

       

       
       

      Thank you

      OTC Report
      @OTCReporter

       

       


      Disclaimer: OTC Report publishes reports providing information on selected companies. OTC Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. OTC Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in PRQR is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. OTC Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. OTC Report does not own any shares of PRQR and does not buy, sell, or trade any shares of PRQR. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by OTC Report. All rights reserved. Our Full Disclaimer: http://otc.report/disclaimer/